Navigation Links
FDA Clears Laser for all Critical Steps in Cataract Surgery: Center For Sight Performs the Most LENSAR Laser Procedures in U.S.
Date:12/16/2012

Sarasota, FL (PRWEB) December 16, 2012

The next generation of refractive cataract surgery reached another significant milestone when the United States Food and Drug Administration (FDA) issued clearance for the LENSAR Laser System to perform corneal incisions – the key step to gaining access into the clouded lens of the eye. The clearance means that patients considering the laser procedure for the removal of their cataracts have another critical tool to help optimize safety, satisfaction and outcomes in connection with their surgery.

The corneal incision made with the laser offers surgeons the ability to execute tiny, ultra-precise, self-sealing incisions. In August, the LENSAR laser was approved by the FDA to create the perfectly round and centered capsulorhexis, as well as to pre-fragment the clouded lens of the eye in order to reduce the required ultrasonic energy to break up and remove the cataract. Sarasota’s Center For Sight the first ophthalmic practice in the nation to acquire this breakthrough technology and has since performed more than 500 refractive cataract surgeries using the laser – making Center For Sight the most experienced user of the LENSAR Laser in the country.

“This is the real deal,” says David W. Shoemaker, M.D., Center For Sight founder and Director of Cataract and Lens Replacement Surgery. “The LENSAR Laser has performed flawlessly each and every time. As a physician and surgeon, I am in awe of the genius of this technology.”

The LENSAR system is the world’s only computer-driven femtosecond cataract laser to provide a real 3-D image of the entire lens of the eye. The ultra precise imaging and biometric measurements ensure exact laser pulse placement. All the incisions made with the laser take less than 15 seconds to complete.

“The advances in ophthalmic surgery are nothing less than astounding. There is no other field of medicine that has progressed at such a dynamic pace. The range of treatment options for patients suffering visual loss just continues to expand,” concludes Dr. Shoemaker.

The next phase of FDA approvals is expected to address using the laser to create limbal relaxing incisions (LRIs) for the treatment of astigmatism. The LRI is an elective surgical procedure that is performed to help the eye return to a normal round shape, thus correcting any poor vision as a result of astigmatism.

About Center For Sight
Center For Sight is among the nation’s leading multi-disciplinary physician groups providing patients worldwide with care in ophthalmology, optometry, dermatology, cosmetic facial surgery and hearing services. In August 2012, Center For Sight earned the distinction of becoming one of the first ophthalmology practices in the United States to introduce the LensAR Laser System for Laser Cataract Surgery. Under the clinical direction of David W. Shoemaker, M.D., and William J. Lahners, M.D., F.A.C.S., Center For Sight has eight offices serving Manatee, Sarasota and Charlotte counties. For more information, visit CenterForSight.net.

Read the full story at http://www.prweb.com/releases/2012/12/prweb10241957.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. San Francisco Bath Salt Company Clears Air About Bath Salt Confusion – Zombies Beware!
2. FDA clears test developed in partnership with VCU researcher
3. No more lying about your age: Scientists can now gauge skin’s true age with new laser technique
4. Beachwood Hair Clinic Announces Laser Hair Removal Services
5. Laser-light testing of breast tumor fiber patterns helps show whose cancer is spreading
6. Studies Show Limits, Promise of Laser Removal of Tattoos
7. Laser treatment improves appearance in burn scars, study shows
8. Higher energies for laser-accelerated particles possible
9. Ultra-short laser pulses for science and industry
10. Screening for breast cancer without X-rays: Lasers and sound merge in promising diagnostic technique
11. Slicing mitotic spindle with lasers, nanosurgeons unravel old pole-to-pole theory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... The StayWell Company ... NCQA. The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart failure, chronic ... organizations that have excellent programs for the delivery and improvement of disease management ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... families and businesses of the greater Fort Collins area, has unveiled a collaboration ... ongoing community involvement program. Donations to this worthy cause may now be made ...
(Date:3/23/2017)... ... , ... ?This conference will prominently feature 150+ Hospital and Health System Executive Speakers including: , ... , 43rd President of the United States of America: George W. Bush , ... Out of the Ring: Sugar Ray Leonard , JD, Chairperson, McGuireWoods LLP: Amber ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... improve all aspects of people’s health and nutrition, announced its product Leyzene is ... , Natural Subsistence develops nutritional supplements that help people improve all aspects of ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The American ... 2017 marks the 40th Anniversary of ABQAURP’s dedication to Health Care Quality and Management ... who have contributed not only to the association, but also to the Health Care ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... On Wednesday, March 22, ... at 5,821.64, up 0.48%; the Dow Jones Industrial ... and the S&P 500 closed at 2,348.45, slightly ... out of nine sectors ended the day in ... on the following Medical Instruments & Supplies equities: ...
(Date:3/23/2017)... 2017 Piramal Pharma ... gibt die Ernennung von Stuart E. Needleman ... globalen Pharmazeutikkunden eine einmalige integrierte End-to-End-Serviceplattform an ... für das erfolgreiche Wachstum und die Umsetzung ... Herr Needleman dafür verantwortlich sein, alle globalen ...
(Date:3/23/2017)... 23, 2017 Merrimack Pharmaceuticals, Inc. (NASDAQ: ... patient in a Phase 1 study of MM-310 in ... encapsulates a novel taxane and targets the EphA2 receptor, ... of many major tumor types, including prostate, ovarian, bladder, ... of this study is an important step in evaluating ...
Breaking Medicine Technology: